Comparison of localized PCa to control group revealed an almost three-fold higher risk of localized PCa among DDR gene mutation carriers as compared to non-carriers (OR 2.84 and 95% CI: 0.75–20.23, p = 0.16), and CHEK2 mutation was responsible for the doubling in risk of localized PCa (OR 1.95, 95% CI: 0.49–14.18, p = 0.51). This evidence concerns the gene CHEK2 and posterior cortical atrophy.